


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (original) A prophylactic and/or therapeutic agent for an allergic disease which contains a compound having an agonistic activity to EP3 receptor.
2. (original) The prophylactic and/or therapeutic agent for an allergic disease according to claim 1, in which the allergic disease is an allergic respiratory disease, allergic nasal disease, allergic skin disease, or allergic ocular disease.
3. (original) The prophylactic and/or therapeutic agent for an allergic disease according to claim 2, in which the allergic respiratory disease is bronchial asthma, pediatric asthma, allergic asthma, or atopic asthma, the allergic nasal disease is allergic rhinitis, vernal catarrh, hay fever, or chronic allergic rhinitis, the allergic skin disease is atopic dermatitis, or the allergic ocular disease is seasonal allergic conjunctivitis, hay fever, or chronic allergic conjunctivitis.
4. (original) The prophylactic and/or therapeutic agent for an allergic disease according to claim 2, in which the allergic respiratory disease is bronchial asthma, pediatric asthma, allergic asthma, or atopic asthma.
5. (currently amended) The prophylactic and/or therapeutic agent for an allergic disease according to claim 1, in which the compound having an agonistic activity to EP3 receptor is a compound represented by the formula (I) or a salt or a solvate thereof:



{wherein R represents an oxo group or a halogen atom, R<sup>1-1</sup> and R<sup>1-2</sup> each independently represent a C1-4 alkyl group, and R<sup>1-3</sup> represents a C1-10 alkyl group, a C2-10 alkenylene group, or a C2-10 alkynylene group substituted by a C1-10 alkyl group, a C2-10 alkenylene group, a C2-10 alkynylene group, a phenyl group, a phenoxy group, a C3-7 cycloalkyl group, or a C3-7 cycloalkyloxy group, wherein the phenyl and cycloalkyl groups may be substituted by 1-3 of C1-4 alkyl groups, C1-4 alkoxy groups, halogen atoms, trihalomethyl groups, or nitro groups} or a salt or a solvate thereof.

6. (original) The prophylactic and/or therapeutic agent for an allergic disease according to claim 5, which is 11 $\alpha$ , 15 $\alpha$ -dimethoxy-9-oxoprost-5Z, 13E-dienoic acid or a salt or a solvate thereof.

7. (original) The prophylactic and/or therapeutic agent for an allergic disease according to claim 1, in which the compound having an agonistic activity to EP3 receptor is misoprostol or sulprostone.

8. (original) A pharmaceutical composition including the compound having an agonistic activity to EP3 receptor described in claim 1 in combination with one or more drugs selected from anti-asthma drugs, inhaled steroid drugs, inhaled  $\beta$ 2 stimulants, methylxanthine asthma drugs, anti-allergy drugs, histamine H1-antagonists, antiinflammatory drugs, anti-choline drugs, thromboxane antagonists, leukotriene antagonists, LTD4 antagonists, PAF antagonists,

phosphodiesterase inhibitors,  $\beta_2$  agonist, steroid drugs, mediator release-suppressing drugs, eosinophil chemotactic-suppressing drugs, disodium cromoglycate, macrolide antibiotics, immune-suppressing agent, and hyposensitization therapy agents.

9. (original) A method of preventing and/or treating an allergic disease, which is characterized by including administering an effective amount of a compound having an agonistic activity to EP3 receptor to a mammal.


10. (original) Use of a compound having an agonistic activity to EP3 receptor for producing a prophylactic and/or therapeutic agent for an allergic disease.

11. (new) The method of preventing and/or treating an allergic disease according to claim 9, in which the allergic disease is an allergic respiratory disease, allergic nasal disease, allergic skin disease, or allergic ocular disease.

12. (new) The method of preventing and/or treating an allergic disease according to claim 11, in which the allergic respiratory disease is bronchial asthma, pediatric asthma, allergic asthma, or atopic asthma, the allergic nasal disease is allergic rhinitis, vernal catarrh, hay fever, or chronic allergic rhinitis, the allergic skin disease is atopic dermatitis, or the allergic ocular disease is seasonal allergic conjunctivitis, hay fever, or chronic allergic conjunctivitis.

13. (new) The method of preventing and/or treating an allergic disease according to claim 11, in which the allergic respiratory disease is bronchial asthma, pediatric asthma, allergic asthma, or atopic asthma.

14. (new) The method of preventing and/or treating an allergic disease according to claim 9, in which the compound having an agonistic activity to EP3 receptor is a compound represented by the formula (I) or a salt or a solvate thereof:



wherein R represents an oxo group or a halogen atom, R<sup>1-1</sup> and R<sup>1-2</sup> each independently represent a C1-4 alkyl group, and R<sup>1-3</sup> represents a C1-10 alkyl group, a C2-10 alkenylene group, or a C2-10 alkynylene group substituted by a C1-10 alkyl group, a C2-10 alkenylene group, a C2-10 alkynylene group, a phenyl group, a phenoxy group, a C3-7 cycloalkyl group, or a C3-7 cycloalkyloxy group, wherein the phenyl and cycloalkyl groups may be substituted by 1-3 of C1-4 alkyl groups, C1-4 alkoxy groups, halogen atoms, trihalomethyl groups, or nitro groups.

15. (new) The method of preventing and/or treating an allergic disease according to claim 14, in which the compound is 11 $\alpha$ ,15 $\alpha$ -dimethoxy-9-oxoprostano-5Z,13E-dienoic acid or a salt or a solvate thereof.

16. (new) The method of preventing and/or treating an allergic disease according to claim 9, in which the compound having an agonistic activity to EP3 receptor is misoprostol or sulprostone.